{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:43:48Z","timestamp":1787021028446,"version":"build-2736575974"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T00:00:00Z","timestamp":1654905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T00:00:00Z","timestamp":1654905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nelarabine is an antineoplastic purine analog used for the treatment of refractory or relapsed T-cell acute lymphoblastic leukemia (T-ALL). The most prominent side effect of nelarabine are neurotoxicity and hematologic disorder, which are considered dose-limiting factors. Although clinical studies have reported myopathy due to nelarabine, actual detailed outcomes were not well-known initial approval. The incidence of nelarabine induced rhabdomyolysis has been reported at 2% in study in children. Cases of rhabdomyolysis have been reported in adults from medical facilities in the United Sates with renal dysfunction or severe muscle symptoms after administration of multiple courses of nelarabine. In this report, we discuss a case of rhabdomyolysis diagnosed after a single course of nelarabine. In this case, creatine kinase (CK) level was elevated in grade 4, without renal dysfunction and severe muscle symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A 46-year-old man from Japan was diagnosed with T-ALL and received a hematopoietic stem cell transplantation in first remission. However, the disease relapsed 6\u2009months after transplantation. Nelarabine was selected as the next-line chemotherapeutic agent. The patient received 1500\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      of nelarabine on day 1 followed by a dose on days 3 and 5. CK levels, which were baseline before treatment, increased to grade 4 (18,620\u2009IU\/L) on the 8th day of treatment. He was diagnosed as rhabdomyolysis due to nelarabine with little possibility of other factors. He complained only of mild pain in his upper extremities and no other symptoms were noticed. The patient was managed with hydration. The pain lasted approximately 7\u2009days, but there were no sequelae secondary to the rhabdomyolysis. Because of the elevation of CK in grade 4, we avoided re-administration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In the patient administrated nelarabine, CK level was elevated in grade 4, without other symptoms of rhabdomyolysis. The results suggest that CK may be elevated at the onset of rhabdomyolysis caused by nelarabine, even in the absence of other symptoms. Therefore, it was suggested that monitoring CK during nelarabine administration is important for detecting rhabdomyolysis before it becomes severe. We consider that CK should be monitored even in absence of symptoms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-022-00247-w","type":"journal-article","created":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T05:02:47Z","timestamp":1654923767000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Nelarabine-induced rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia: a case report"],"prefix":"10.1186","volume":"8","author":[{"given":"Akari","family":"Utsumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4812-9420","authenticated-orcid":false,"given":"Takaaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiaki","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Sakaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itsuko","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,11]]},"reference":[{"issue":"3","key":"247_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11864-020-0712-8","volume":"21","author":"KA Hodby","year":"2020","unstructured":"Hodby KA, Marks DI. Recent advances in the management of acute lymphoblastic leukaemia. Curr Treat Options in Oncol. 2020;21(3):23.","journal-title":"Curr Treat Options in Oncol"},{"issue":"9","key":"247_CR2","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1016\/j.clinthera.2007.09.002","volume":"29","author":"LW Buie","year":"2007","unstructured":"Buie LW, Epstein SS, Lindley CM. Nelarabine: a novel purine antimetabolite antineoplastic agent. Clin Ther. 2007;29(9):1887\u201399.","journal-title":"Clin Ther"},{"key":"247_CR3","unstructured":"Center for drug evaluation and research. Medical review(s) application number:21-877 [cited 2022 February 10].\u00a0https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=021877."},{"key":"247_CR4","unstructured":"FDA Prescribing information Nelarabine (Updated 07\/2019). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021877s010lbl.pdf. Cited 2022 Feb 10."},{"issue":"29","key":"247_CR5","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1200\/JCO.2018.77.7250","volume":"36","author":"SS Winter","year":"2018","unstructured":"Winter SS, Dunsmore KP, Devidas M, et al. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's oncology group AALL0434 methotrexate randomization. J Clin Oncol. 2018;36(29):2926\u201334.","journal-title":"J Clin Oncol"},{"key":"247_CR6","first-page":"825670","volume":"2015","author":"M Haider","year":"2015","unstructured":"Haider M, Rizvi SA, Kasi PM. Nelarabine associated myotoxicity and rhabdomyolysis. Case Rep Hematol. 2015;2015:825670.","journal-title":"Case Rep Hematol"},{"issue":"11","key":"247_CR7","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1080\/10428194.2020.1791852","volume":"61","author":"RK Pandey","year":"2020","unstructured":"Pandey RK, DiPippo A, Kadia T, et al. Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2020;61(11):2775\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"247_CR8","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/leu.2017.283","volume":"32","author":"T Sakura","year":"2018","unstructured":"Sakura T, Hayakawa F, Sugiura I, et al. High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG. Leukemia. 2018;32(3):626\u201332.","journal-title":"Leukemia"},{"issue":"2","key":"247_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345.","journal-title":"Clin Pharmacol Ther"},{"key":"247_CR10","unstructured":"Stanley M, Chippa V, Aeddula NR, Quintanilla Rodriguez BS, Adigun R. Rhabdomyolysis. 2021. StatPearls. https:\/\/pubmed.ncbi.nlm.nih.gov\/28846335\/."},{"issue":"4","key":"247_CR11","doi-asserted-by":"publisher","first-page":"e228673","DOI":"10.1136\/bcr-2018-228673","volume":"12","author":"A Pissarra","year":"2019","unstructured":"Pissarra A, Malheiro M, Matos LV, Pl\u00e1cido AN. Severe rhabdomyolysis related to oxaliplatin adjuvant therapy for colorectal cancer. BMJ Case Rep. 2019;12(4):e228673.","journal-title":"BMJ Case Rep"},{"issue":"4","key":"247_CR12","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/ajh.10152","volume":"70","author":"CI Truica","year":"2002","unstructured":"Truica CI, Frankel SR. Acute rhabdomyolysis as a complication of cytarabine chemotherapy for acute myeloid leukemia: case report and review of literature. Am J Hematol. 2002;70(4):320\u20133.","journal-title":"Am J Hematol"},{"issue":"26","key":"247_CR13","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.2174\/092986706778742918","volume":"13","author":"T Robak","year":"2006","unstructured":"Robak T, Lech-Maranda E, Korycka A, Robak E. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Curr Med Chem. 2006;13(26):3165\u201389.","journal-title":"Curr Med Chem"},{"issue":"1","key":"247_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1152\/physrev.00043.2011","volume":"93","author":"H Yin","year":"2013","unstructured":"Yin H, Price F, Rudnicki MA. Satellite cells and the muscle stem cell niche. Physiol Rev. 2013;93(1):23\u201367.","journal-title":"Physiol Rev"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-022-00247-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-022-00247-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-022-00247-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T05:13:04Z","timestamp":1654924384000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-022-00247-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,11]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["247"],"URL":"https:\/\/doi.org\/10.1186\/s40780-022-00247-w","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,11]]},"assertion":[{"value":"28 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}